Table 1

Clinical characteristics.

Test cohort

Validation cohort

High EF

Low EF

P value

(n = 16)

(n = 16)

(high vs low EF)

(n = 115)

4-months EF, % (median-range)

63

45-73

35

20-40

0.0003

40

15-86

Age, y (median-range)

56

43-84

68

38-83

0.57

56

32-90

Sex (male, n, %)

13

81%

13

81%

1

98

85%

Body Mass Index (median-range)

28

23-35

26

20-38

0.25

27

19-43

Serum markers (median-range)

Troponin T (ng/mL)

0.78

0.06-10.69

11.64

1.46-26.1

0.007

4.76

0.03-26.1

CPK (units/L)

762

603-3798

4860

1015-9383

< 0.001

1978

602-9383

Cardiovascular history, n (%)

Prior MI

2

13%

3

19%

0.64

7

6%

CABG

0

0%

1

6%

0.33

3

3%

PTCA

1

6%

2

13%

0.56

11

10%

Diabetes

4

25%

6

38%

0.46

22

19%

Hypertension

6

38%

7

44%

0.73

47

41%

Hypercholesterolemia

7

44%

9

56%

0.50

45

39%

Tobacco

4

25%

5

31%

0.71

53

46%

Medications, n (%)

Beta-blockers

16

100%

14

88%

0.16

98

85%

Calcium antagonists

3

19%

0

0%

0.08

0

0%

Nitrates

6

38%

6

38%

1

31

27%

ACE inhibitors

10

63%

10

63%

1

51

44%

Statins

14

88%

14

88%

1

89

77%

Angiotensin receptor inhibitors

2

13%

0

0%

0.16

1

1%

All MI patients had successful mechanical reperfusion and stenting of the infarct artery within 12 hours of chest pain onset. All patients received Aspirin, Clopidogrel, Heparin and Abciximab in the presence of a large thrombus.

ACE: Angiotensin Converting Enzyme; CABG: Coronary Artery Bypass Grafting; EF: Ejection Fraction; PTCA: Percutaneous Transluminal Coronary Angioplasty; MI: Myocardial Infarction.

Devaux et al. BMC Medical Genomics 2011 4:83   doi:10.1186/1755-8794-4-83